16 completed, 6 terminated, 3 recruiting, 2 not yet recruiting. 29 Phase 2, 7 Phase 3, 6 Phase 1.
Follow Ichthyosis: new trials by email Literature Review of Ichthyosis trials Research Report on Ichthyosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epidermal Growth Factor Receptor Inhibition for Keratinopathies Erlotinib - Epidermolytic Ichthyosis, Palmoplantar Keratoderma | Phase 1 / Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-07-01 | 2026-08-03 |
| Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003 - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 16 | 2026-03-19 | 2026-09-28 |
| Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 8 | 2025-10-06 | 2026-08-31 |
| Efficacy of Injectable Gentamicin in Hereditary Ichthyosis Gentamicin Injectable Solution - Ichthyosis | Phase 2 | Not yet recruiting | University Hospital, Toulouse | 26 | 2024-09-01 | 2024-09-05 |
| Comparison of Rimegepant and Placebo for Pain in IBS Rimegepant 75 MG [Nurtec] - Irritable Bowel Syndrome | Phase 2 | Completed | Mayo Clinic | 39 | 2024-06-06 | 2026-10-15 |
| A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses deucravacitinib - Epidermolysis Bullosa Simplex, Ichthyosis | Phase 2 | Completed | Centre Hospitalier Universitaire de Nice | 8 | 2024-03-18 | 2026-10-16 |
| A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome DS-2325a, Placebo - Netherton Syndrome | Phase 1 / Phase 2 | Terminated | Daiichi Sankyo | 9 | 2023-09-28 | 2026-05-14 |
| A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | Boehringer Ingelheim | 43 | 2023-06-12 | 2026-03-12 |
| Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 20 | 2023-03-14 | 2026-08-31 |
| ADX-629 Therapy for Sjogren-Larsson Syndrome ADX-629 - Sjogren-Larsson Syndrome | Phase 1 / Phase 2 | Completed | University of Nebraska | 8 | 2023-01-02 | 2026-05-05 |
| Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle - Netherton Syndrome | Phase 2 / Phase 3 | Active not recruiting | Quoin Pharmaceuticals | 30 | 2022-06-23 | 2026-03-16 |
| A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome SXR1096 cream, Placebo cream - Netherton Syndrome | Phase 1 / Phase 2 | Completed | Sixera Pharma | 9 | 2021-12-07 | 2025-12-16 |
| A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis Imsidolimab, placebo - Ichthyosis | Phase 2 | Terminated | Vanda Pharmaceuticals | 5 | 2021-01-25 | 2025-09-16 |
| A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome Dupilumab Prefilled Syringe, Placebo Prefilled Syringe - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | University Hospital, Toulouse | 10 | 2020-07-23 | 2026-09-21 |
| A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis Isotretinoin, Vehicle - Congenital Ichthyosis | Phase 2 | Completed | LEO Pharma | 34 | 2019-12-03 | 2026-05-22 |
| Use of Propranolol Hydrochloride in the Treatment of Metastatic STS Propranolol Hydrochloride, Doxorubicin - Malignant Soft Tissue Sarcoma | Phase 2 | Unknown | Ain Shams University | 50 | 2019-08-30 | 2018-02-23 |
| A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis CD5789 Cream 200 µg/g, CD5789 Cream 100 µg/g, CD5789 Cream Vehicle - Lamellar Ichthyosis | Phase 2 | Terminated | Mayne Pharma International Pty Ltd | 65 | 2019-05-01 | 2023-08-14 |
| A Six Week Topical Cream Study for Subjects With Ichthyosis Vulgaris 146-9251 cream, Vehicle cream - Ichthyosis Vulgaris | Phase 2 | Completed | Crown Laboratories, Inc. | 80 | 2017-04-25 | 2021-08-10 |
| A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis PAT-001, 0.1%, PAT-001, 0.2%, Vehicle for PAT-001 0.1% - Congenital Ichthyosis | Phase 2 | Completed | Patagonia Pharmaceuticals, LLC | 19 | 2017-03-08 | 2021-09-29 |
| The Efficacy and Safety of Secukinumab in Patients With Ichthyoses Secukinumab, Placebo - Ichthyosis, Autosomal Recessive Congenital Ichthyosis | Phase 2 | Completed | Northwestern University | 20 | 2016-12-01 | 2021-08-25 |
Showing 20 of 29. Sign in to see all of them.
Netherton Syndrome (11) · Ichthyosis Bullosa of Siemens (4) · Ichthyosis Vulgaris (3) · Ichthyosis, Lamellar (3) · Ichthyosis, X-Linked (3) · Irritable Bowel Syndrome (3) · Constipation (2) · Hyperkeratosis, Epidermolytic (2) · Sjogren-Larsson Syndrome (2) · Cerebral Palsy (1) · Epidermolysis Bullosa Simplex (1) · Ichthyosiform Erythroderma, Congenital (1) · Intellectual Disability (1) · Keratoderma, Palmoplantar (1)
Congenital Abnormalities (29) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (29) · Keratosis (29) · Skin Abnormalities (29) · Skin Diseases (29) · Skin and Connective Tissue Diseases (29) · Genetic Diseases, Inborn (27) · Infant, Newborn, Diseases (26) · Skin Diseases, Genetic (26) · Ichthyosiform Erythroderma, Congenital (13) · Abnormalities, Multiple (12) · Metabolic Diseases (5) · Metabolism, Inborn Errors (5) · Nutritional and Metabolic Diseases (5)
Doxorubicin (2) · Trabectedin (2) · ADX-629 (1) · Adalimumab (1) · Chenodeoxycholic Acid (1) · Erlotinib Hydrochloride (1) · Glucagon-Like Peptide 1 (1) · Injections (1) · Isotretinoin (1) · Propranolol (1) · WAS protein, human (1) · deucravacitinib (1) · glucagon-like peptide (7-37), valyl(10)- (1) · liarozole (1) · pimecrolimus (1)
Quoin Pharmaceuticals (4) · Mayo Clinic (3) · Northwestern University (2) · University Hospital, Toulouse (2) · Ain Shams University (1) · Aldeyra Therapeutics, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Boehringer Ingelheim (1) · Centre Hospitalier Universitaire de Nice (1) · Children's Hospital of Philadelphia (1) · Crown Laboratories, Inc. (1) · Daiichi Sankyo (1) · Dynogen Pharmaceuticals (1) · Grupo Espanol de Investigacion en Sarcomas (1) · Italian Sarcoma Group (1)
United States (19) · France (9) · Germany (4) · Australia (3) · Canada (3) · Italy (3) · United Kingdom (3) · Israel (2) · Netherlands (2) · Spain (2) · Sweden (2) · Austria (1) · Belgium (1) · Bulgaria (1) · China (1)
Tony Andrasfay (2) · Albert C Yan, MD (1) · Amy Paller (1) · Amy Paller, MD (1) · Andres Poveda, Ph.M. (1) · Christine Bodemer, MD, PhD (1) · Christine Chiaverini (1) · Emma Guttman-Yassky, MD, PhD (1) · Javier Martin Broto, PhM (1) · Keith A. Choate, MD (1) · Koen van Rossem, MD, PhD (1) · Maarten de Chateau, MD PhD (1) · Michael Camilleri (1)
PMID 20083693, PMID 20691689, PMID 22517769, PMID 24102348, PMID 35218370, PMID 37170057, PMID 41637861
UL1RR024150 (2), 1RC1DK086182 (1), 2008 (1), R01DK054681 (1), R01DK079866 (1)